SANTA CLARA, Calif. & SPOKANE, Wash.–Agilent Technologies Inc. (NYSE:A – News) and Signature Genomic Laboratories LLC (Signature) today announced they have signed a long-term supply agreement in which Agilent will supply custom oligonucleotide microarrays to Signature and its customers based on the Signature-designed SignatureChip Oligo Solution (SignatureChipOS). Terms of the agreement were not disclosed.

The SignatureChipOS is designed for the detection of chromosome abnormalities in individuals with mental retardation/developmental delay, autism and congenital anomalies. The 105,000-feature, 60-mer microarray covers more than 150 syndromes, the subtelomeric and pericentromeric regions, and more than 500 genes in important developmental pathways.

“We’re very pleased about this agreement, which is the latest example of how the marketplace is recognizing the value of our highly flexible, high-quality custom oligonucleotide microarray production capability,” said Yvonne Linney, Ph.D., Agilent vice president and general manager, Genomics. “We’re delighted to work with Signature Genomic Laboratories, which specializes in microarray technology and is an innovative leader in microarray testing.”

“We are committed to giving our customers the best services and technology available, and this agreement reflects this focus,” said Lisa G. Shaffer, Ph.D., president and CEO of Signature. “Oligo arrays have improved dramatically in the past few years, and we are delighted there are now oligos that meet our high standards. This supply agreement also allows our Genoglyphix customers the opportunity to use high-quality oligo arrays for research applications in their laboratories.”

About Signature Genomic Laboratories

Genoglyphix is the innovative software created and used by Signature Genomic Laboratories. Information about Genoglyphix is available at www.genoglyphix.com.

The SignatureChipOS was developed and its performance characteristics determined by Signature Genomic Laboratories as required by CLIA ‘88 regulations. It has not been cleared or approved for specific uses by the U.S. Food and Drug Administration. Pursuant to the requirements of CLIA ‘88, Signature Genomic Laboratories has established and verified the test’s accuracy and precision.

Signature Genomic Laboratories, founded in 2003, was the first laboratory to provide microarray-based cytogenetic diagnostics with its proprietary SignatureChip and is the leader in providing microarray-based chromosome analysis. Signature’s worldwide client base includes clinical geneticists, neurologists, pediatricians, neonatologists, obstetricians, and the research community. Signature is CAP accredited, CLIA certified, and has clinical licenses from California, Rhode Island and Florida. Additional information about Signature Genomic Laboratories is available at www.signaturegenomics.com.

About Agilent in Genomics

Agilent is a leading provider of research microarrays used to analyze gene expression, microRNA, comparative genomic hybridization and ChIP-on-chip. More information about Agilent microarrays is available at www.opengenomics.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A – News) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.4 billion in fiscal year 2007. Information about Agilent is available on the Web at www.agilent.com.

NOTE TO EDITORS: Press releases, photography and other information can be accessed on the Agilent Life Sciences and Chemical Analysis newsroom at www.agilent.com/about/newsroom/lsca.

Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.